A sumatriptan iontophoretic transdermal system for the acute treatment of migraine
Headache: The Journal of Head and Face Pain, 06/04/2012
Clinical Article
Goldstein J et al. – The sumatriptan iontophoretic transdermal system is effective and well tolerated and may be particularly useful in patients with migraine–related gastrointestinal symptoms such as nausea.
Methods- Patients were randomized to treat a single moderate to severe migraine attack with the sumatriptan iontophoretic transdermal system or placebo.
- The primary endpoint was the proportion of patients who were headache pain free 2 hours after patch activation.
- Other endpoints included the proportions of patients who reported headache pain relief and freedom from nausea, photophobia, and phonophobia; rescue medication use; and tolerability.
- 469 patients were treated.
- Significantly more patients treated with the sumatriptan iontophoretic transdermal system compared with placebo experienced freedom from headache pain, nausea, photophobia, and phonophobia 2 hours after patch activation; experienced rapid and sustained headache pain relief; and used less rescue medication.
- Treatment–emergent adverse events were reported by 50% and 44% of patients treated with the sumatriptan iontophoretic transdermal system and placebo, respectively.
- Most events were transient mild–to–moderate application–site reactions.
